Skip to main content

Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.

Fund Technology Growth EIS

AlgaeCytes: biomanufacturing company engaged in the production of natural, vegan, sustainably-sourced products promoting healthy living from microalgae. The Company is well-positioned to be a first-mover meeting the growing demand for its initial lead product, Omega-3 EPA, which is natural, vegan and wholly-traceably.

The Investment Opportunity

AlgaeCytes, with its patented and proprietary technology, is a company specialising in the production of high-quality EPA oils. EPA and DHA are the main oils in the Omega 3 sector, derived from freshwater algae.

AlgaeCytes grows microalgae in enclosed photobioreactors to make consistently high potency, traceable, Non-GMO, vegetarian, and sustainable ingredients primarily for premium priced products. The Company intends to target the rapidly growing personal care, healthcare and nutra-therapeutics markets.

Omega 3 oils are increasingly in high demand within a multitude of sectors including healthcare, food and drink, sports, cosmetics, personal and the oral care industries, due to its many health-promoting qualities. The human body cannot naturally produce omega 3 oils and so is traditionally sourced from wild-catch deep sea fish, other marine animals, algae and vegetables (including flaxseed).

AlgaeCytes’ primary product is the omega 3 EPA oils. EPA oils are recognised to enhance heart, cardiovascular, neuro and skin health, and lessen inflammation. Other products produced by the Company include beta-carotene (vitamin A source) and an agricultural crop bio-stimulant from algae.

Algaecytes Limited Website
Milestones to Date

Secured an Innovate UK grant for circa £1m.


Trade names “AVEPA”, “AVEPA Daily” and “AVEPA Max” confirmed for the AlgaeCytes’ products.

EPA Pilot plant commissioned with products sent to notable world-wide interested customers. 


Commercial Factory FEED report finalized that details the scale-up needed to build a 50 MT annual capacity commercial facility.

Financial model finalised and validated for the future build of a full-scale commercial plant, which shows EBITA of £7.5 million for year 1 of a full year’s production.


Clear path to securing £50 million in capital spend to secure the facility as well as a location for new commercial facility.

Shortlisted as a finalist for Best Investment in Sustainable Innovation at the UKBAA Angel Investment Awards.

Site for first commercial scale plant in Germany approved.

The Company signed a term sheet for 5 million euros from German regional development fund.

The Company has further developed its IP portfolio.

Risks and Important Information

This page is a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000. The content of the page has been approved by Deepbridge Capital LLP. The Company may not gain the commercial traction that is forecast, it could experience development problems and may not be able to achieve its objectives. Please note that these risks are by no means exhaustive and there may be other risks which could have a material adverse impact on the Company’s financial performance. The content should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors could lose the total value of their investment. Investments in small unquoted companies carry a high- level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Deepbridge does not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.